Indexed with PubMed and Science Citation Index (E) 
Users online: 1056 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
   Next article
   Previous article 
   Table of Contents
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Article in PDF (496 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

  In this article
   Classification o...
   1. Primary Derma...
   2. Dermatoses As...
   Article Tables

 Article Access Statistics
    PDF Downloaded1041    
    Comments [Add]    
    Cited by others 2    

Recommend this journal


Year : 2010  |  Volume : 76  |  Issue : 4  |  Page : 328-340

Neonatal dermatological emergencies

Department of Dermatology, Venereology and Leprosy, Shri B. M. Patil Medical College, Hospital and Research Center, BLDE University, Bijapur, Karnataka, India

Date of Web Publication21-Jul-2010

Correspondence Address:
Arun C Inamadar
Department of Dermatology, Venereology and Leprosy, Shri B.M. Patil Medical College, Hospital and Research Center, BLDE University, Bijapur - 586 103, Karnataka
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0378-6323.66575

Rights and Permissions


The neonates are unique in several ways in comparison with older children and adults which render them highly susceptible to severe, sometimes life threatening dermatological disorders. The neonatal dermatological emergencies are a diagnostic and therapeutic challenge. A wide range of dermatoses such as infections, genodermatoses, metabolic disorders and vascular tumors may require emergency care. The clinical presentation also varies from generalized involvement of skin to localized disease with or without systemic symptoms. Irrespective of the etiology and clinical presentation, these disorders are associated with significant morbidity and mortality. With the availability of effective drugs and monitoring facilities, and awareness of need for immediate care, there has been a significant decline in the fatality rate associated with neonatal dermatological emergencies. Knowledge of clinical presentations, rapid diagnostic methods, emergency care and monitoring of progress of the disease helps in comprehensive multidisciplinary care of neonates with these disorders.

Keywords: Neonatal dermatological emergencies, neonatal erythroderma, neonatal intensive care

How to cite this article:
Ragunatha S, Inamadar AC. Neonatal dermatological emergencies. Indian J Dermatol Venereol Leprol 2010;76:328-40

How to cite this URL:
Ragunatha S, Inamadar AC. Neonatal dermatological emergencies. Indian J Dermatol Venereol Leprol [serial online] 2010 [cited 2020 Nov 29];76:328-40. Available from:

  Introduction Top

Dermatological emergencies comprise diseases that demand early diagnosis, hospitalization, careful monitoring and multidisciplinary intensive care to minimize the associated morbidity and mortality. An intensive care unit and a well synchronized team of dermatologist, pediatrician and skilled nursing staff are necessary for the management of patients. [1] This review is focused on clinical presentations, immediate care and monitoring of dermatoses or clinical syndromes which almost always present with significant morbidity and mortality in neonates [Table 1].

In a hospital-based Indian study, of total emergency dermatological referrals, 15.5% were neonates, 9.7% were infants, 36.9% were preschool and 37.2% were school going children. Genodermatoses like epidermolysis bullosa, collodion baby and Harlequin ichthyosis (37.5%), and staphylococcal scalded skin syndrome (SSSS) (31.7%) were common in neonates whereas severe atopic and seborrheic dermatitis were common in infants. In preschool and school going children, infections (42.1%) and cutaneous drug reactions (56.4%), respectively, formed majority of cases. [2]

The first 4 weeks of life of an infant is considered as the neonatal period. Neonates are unique in several ways (increased body surface to weight ratio, immature kidney and immunity, risk of intrauterine infection and transepidermal water loss) in comparison with older children and adults which render them highly susceptible to severe dehydration and infections either primary or secondary.

  Classification of Neonatal Dermatological Emergencies Top

The neonatal dermatological emergencies can be clinically classified into two groups: primary dermatological emergencies and dermatoses associated with medical or surgical emergencies [Table 2]. In the former group, the involvement of skin is the primary cause for the mortality or is the major manifestation, and in the latter, cutaneous manifestations are the indicators of impending or underlying severe systemic involvement.

  1. Primary Dermatological Emergencies Top

A. Neonatal erythroderma (red scaly baby)

Neonatal erythroderma is a rare and potentially life threatening condition irrespective of underlying etiology. The exact incidence of the condition is not known. A hospital-based retrospective study of pediatric patients (neonates and infants) attending a tertiary care children hospital in North India reported an incidence of 0.11% (20/19000). [3]

Causes of neonatal erythroderma [Table 2]

In a retrospective study of erythroderma during the first year of life, 32% of cases had congenital onset of the disease. All the cases belonged to ichthyosis group except for one case of Omenn syndrome. Forty percent of ichthyotic disorders presented with collodion membrane. [4] In a hospital-based, retrospective study from India, ichthyosiform erythroderma constituted 25% of cases. [5] In this study, infections were also included unlike the previous study. [4] Rare causes of neonatal erythroderma include congenital erythrodermic psoriasis, diffuse cutaneous mastocytosis, graft versus host disease and congenital erythrodermic pityriasis rubra pilaris. [6]

Clinical features

The clinical presentation is characterized by generalized erythema and scaling irrespective of the underlying disease. However, certain clinical clues may help in establishing the etiology of the condition [Table 3]. [3],[4],[6] Apart from clinical presentations, family history of erythroderma and atopy, sibling mortality and consanguineous marriage also help in the differential diagnosis. Sibling mortality and family history of erythroderma have been reported in 57% and 66% of cases of Omenn syndrome and Netherton syndrome, respectively. Consanguineous marriage has been reported in 25%, 88% and 33% cases of ichthyoses, Netherton syndrome and primary immunodeficiency respectively. Family history of atopy can be elicited in 33% and 43% of cases of Netherton syndrome and Omenn syndrome, respectively. [4]

Despite clinical and laboratory evaluation, some cases remain undiagnosed. These neonates presented with severely pruritic erythroderma, marked induration of skin, severe alopecia, nail abnormalities, failure to thrive, lymphadenopathy and hepatosplenomegaly. Family history of atopy may be present in 60% of cases. Severe systemic infection occurs in almost all the cases. [4] Leiner's disease is another such entity applied to a neonatal erythroderma after other causes have been ruled out. A follow- up study of five infants with Leiner's phenotype revealed immunological abnormalities in all the cases; one had hypogammaglobulinemia, one had combined immunodeficiency which was later diagnosed as Omenn syndrome and three were diagnosed as Netherton syndrome with elevated IgE levels. [7]

Consequences of neonatal erythroderma

The diagnosis of the disease is usually delayed. Hence, the management of the condition is usually aimed at prevention or treatment of consequences and/ or complications of erythroderma. The loss of cutaneous barrier results in interrelated alterations in transepidermal water loss, caloric or heat loss and metabolic rate.

Effect on transepidermal water loss: Normally, in addition to mandatory water loss by the kidneys and gastrointestinal system, additional water losses occur due to evaporation from the skin and respiratory tract. The latter two are not measured usually and hence termed as insensible water loss (IWL). Transepidermal water loss (TEWL) contributes 70% of this insensible water loss. [8]

The TEWL reflects both skin immaturity and the larger surface area to weight ratio. In a normal full-term infant, the TEWL is about 6-8 g/m 2 /h (12ml/kg/day). Whereas in preterm infants born at 24-25 weeks gestation, TEWL is 60 g/m 2 /h (about 140 ml/kg/day) and then it falls exponentially to 45 g/ m 2 /h by 3 rd day and to 24 g/m 2 /h by 28 th day. By 32 weeks of gestation, TEWL normalizes along with skin maturity to that of normal full term infant. The severity of TEWL also depends on ambient humidity. A high ambient humidity reduces TEWL especially in premature infants. In term infants, the susceptibility to change in ambient humidity is very low. [9,10] The TEWL depends on various factors such as ambient and body temperature, microenvironment of neonatal care, activity of baby, phototherapy, gestational age of the baby and skin trauma. [11]

In pediatric patients with ichthyosis, the total body TEWL, depending upon the severity and genetic heterogeneity, ranges from 746 ± 468 ml/day (mean basal TEWL of 39.6 ± 20.6 ml/m 2 /h compared to upper limit of normal 8.7 ml/m 2 /h) in contrast to 209 ml/day seen in age-matched children with competent skin barrier. [12] An estimation of TEWL from normal and abnormal skin of a collodion baby using evaporimeter at day 4 demonstrated a loss of 18 ± 2 g/m 2 /h and 112 ± 2 g/m 2 /h of water respectively, at room temperature of 27 0 C and relative humidity of 25%. The same reduced significantly, in parallel with the clinical improvement of the skin at day 30 to 5.5 ± 2 g/m 2 /h and 16 ± 2 g/m 2 /h respectively, at room temperature of 23 0 C and relative humidity of 37%. [11] This significant reduction in TEWL underlines the importance of maintenance of skin barrier, ambient humidity and temperature.

Effect on caloric or heat loss and metabolic rate: The TEWL is always accompanied by heat loss at the rate of 0.58 kcal/ ml. The total caloric loss from daily TEWL in pediatric patients with ichthyosis ranges from 84 to 1015 kcal (21±9.8 kcal/kg/day with a mean of 433± 272 kcal/day) in contrast to 41- 132 kcal/ day seen in age-matched children. [12] Therefore, it is very difficult to regulate temperature in such babies and hyperpyrexia may occur if the ambient temperature is too high. [9],[11]

This evaporative caloric loss is compounded by cutaneous hyperplasia and inflammation. These, at the same time, result in increased metabolic rate. Also the resting energy expenditure in the infants with ichthyosis is usually 19% or higher than predicted. Hence the severity of the barrier defect correlates with the increased metabolic demand. [13]

Complications of neonatal erythroderma

The neonates with erythroderma are at increased risk of hypernatremic dehydration, severe systemic infections, hypoalbuminemia and hyperpyrexia or hypothermia as a result of consequences of erythroderma (see above). These complications are more pronounced in collodion baby, Harlequin ichthyosis, severe lamellar ichthyosis, Netherton syndrome and Omenn syndrome resulting in significant mortality and morbidity. Increased skin fragility, fissures, cracks, erosions or immunodeficiency in these disorders result in severe septicemic infections. [3],[4],[6]

Laboratory investigations

The laboratory evaluation of neonatal erythroderma is facilitated by a few investigations. Serum IgE levels are markedly elevated in Netherton and Omenn syndrome. Histopathological study of skin biopsy specimens preferably taken simultaneously from 2 or 3 different sites contributes to the specific diagnosis only in 45% of cases. Significant orthokeratosis with corneocytes arranged in laminated and compact fashion, prominent hypergranulosis, acanthosis, and absent or few inflammatory cells suggest ichthyoses except Netherton syndrome. In bullous ichthyosiform erythroderma, epidermolytic hyperkeratosis is seen. Omenn syndrome and graft versus host disease are characterized by dermal and epidermal lymphocytic infiltration and keratinocyte necrosis with satellite lymphocytes. Serum electrolyte and albumin levels should be monitored because of increased risk of hypernatremic dehydration (Sodium >160mmol/l), and hypoalbuminemia from enteral and transcutaneous loss of proteins. Bacterial culture from skin swabs from different sites or blood is indicated if secondary bacterial infection or septicemia is suspected. [3],[4],[6]


Regardless of underlying disease, the management of neonatal erythroderma includes fluid and electrolyte balance, correction of caloric and protein intake, and prevention and treatment of infections. [4] Specific therapy is started once the diagnosis of underlying disease is established.

Fluid and electrolyte balance: In neonatal erythroderma, satisfactory fluid and electrolyte balance is achieved by reduction of high TEWL, and parenteral fluid and electrolyte replacement [Table 4]. Initial fluid calculation is a matter of best clinical judgment influenced by changing clinical circumstances. [9] The adequacy of fluid replacement should be monitored carefully using clinical and laboratory parameters [Table 5]. Further fluid and electrolyte replacement is guided by these parameters. [8]

Protein and Caloric intake: The supplementation of protein and calorie in neonates with erythroderma must meet the demands of hypermetabolic state and requirements of normal growth and development. There is a little consensus on the formula to compute the amount of calorie delivery or resting energy expenditure. Recently, there has been a change in concepts and guidelines of nutritional support in critically ill children [Table 6]. [14]

As the neonate improves and hypermetabolic state reverses, the calorie supply may be increased to even hypercaloric nutritional support. Then the energy needs are roughly equal to the daily fluid requirements of infants. An estimated energy intake of 120-130 kcal/kg/day is required to achieve a normal weight gain of 15 g/kg/day. The energy intake can be increased by 10-30% depending upon the stressful conditions. The resting energy expenditure in infants with ichthyosis is usually 19% or higher than predicted. [13] The calorie lost from total daily TEWL (see above) may provide a guide to replacement therapy. The glucose infusion should provide 50- 70% of energy requirement. Rest of the calorie is provided by lipids. At least 3% of calorie should be derived from essential fatty acids. Protein needs should be considered in conjunction with energy. The daily requirement of protein is 3-3.5 g/kg/day. Normal requirements of vitamins and minerals should be met as there is little published data of these nutrients in sick children. [14]

Treatment of infections: Widespread cutaneous colonization and/or infection especially with Staphylococcus aureus are common in neonates with erythroderma. Antibiotics should be selected based on the results of culture and sensitivity. Parenteral antibiotics are preferred in neonates. [4]

Specific therapy: Topical application of bland emollients such as petrolatum or white soft paraffin helps in maintenance of barrier function of stratum corneum. [4],[6] The efficacy of systemic retinoids in the treatment of ichthyosis except Netherton syndrome is well established. However, risk/ benefit ratio is considered before using retinoids because of increased skin fragility and decreased barrier competence induced by them. The use of topical retinoids and calcipotriol in generalized ichthyosis is limited by their irritancy and expense. [15] Omenn syndrome and severe combined immunodeficiency may need bone marrow transplantation. [4]

B. Neonatal cutaneous infections

0Newborns are susceptible to various infections during the perinatal period. Premature and low birth weight infants are particularly predisposed to fatal neonatal infectious disorders. These include staphylococcal scalded skin syndrome (SSSS), necrotizing fascitis, neonatal varicella, neonatal herpes simplex infection (HSV) and cutaneous candidiasis [Table 7].

Staphylococcal scalded skin syndrome follows trivial infective foci elsewhere in the body. The diagnosis is mainly based on typical clinical features [Table 7]. The culture from lesion is sterile because the infection is caused by exfoliative toxins (ET)-A and ET-B produced by Staphylococcus aureus. [16],[17] Blood culture is usually negative in SSSS as the organism is rarely invasive. However, the neonates are at risk of Gram negative septicemia especially Pseudomonas aerugenosa. Tzanck smear from the ruptured blister may aid in the rapid diagnosis. SSSS responds well to antistaphylococcal antibiotics and supportive therapy. [18]

Necrotizing fascitis is primarily a disease of the adults. Though rare in neonates, NF is characterized by a fulminant course. The infection starts as a minimal rash, erythema, induration or cellulitis at the site [Table 7]. Non-invasive imaging techniques help in rapid diagnosis. [19] In probable cases of NF, the lack of resistance of fascial plane on finger pressure or blunt probe dissection during surgery establishes the diagnosis. [20] The infection is polymicrobial in almost 75% of cases on wound culture. The monomicrobial infection which occurs in 25% of cases is usually caused by Staphylococcus aureus. A positive blood culture has been reported in 50% of cases among which 75% were monomicrobial and 25% were polymicrobial. Other laboratory findings include leukocytosis with a shift to left, and thrombocytopenia in about half of the patients. [19] Immediate surgical intervention with antibiotics [21] is required because a prolonged lapse of time between the hospital admission and surgical debridement is the only potential determinant associated with an unfavorable outcome. [22] Death usually occurs in 59% of cases before or shortly after surgery due to septicemic shock, disseminated intravascular coagulation and/ or multiple organ failure. [19]

Neonatal varicella is usually transmitted from maternal varicella occurring during last 3 weeks of pregnancy. The manifestation of neonatal varicella during first 10-12 days of life suggests transplacental transmission of the disease. Postnatally acquired neonatal varicella presents after 12 days of life. [23] The severity and mortality of neonatal varicella depends on the day of onset of rash in the mother and neonate [Table 7]. [24],[25] Disseminated infection with pneumonia, hepatitis or meningo-encephalitis occurs in 20-50% of cases with a mortality of 20-23%. Death from severe pneumonitis and respiratory distress often occurs 4-6 days after the onset of lesions. [23]

Neonatal HSV infection is transmitted from the mother during one of the three distinct time intervals, intrauterine (5%), peripartum (85%) and post partum (10%). [26] Infants born to mothers who have first episode of genital herpes near term are at increased risk of developing neonatal herpes than those born to mothers with recurrent infection. [27] The clinical types of neonatal HSV infection includes skin, eye and/ or mouth (SEM) disease accounting for 45% of cases, disseminated disease accounting for 25% of cases and central nervous system (CNS) disease with or without SEM accounting for 30% of cases. [28] The neonatal HSV infection is considered as spectrum of disease because of overlapping signs and symptoms. Skin vesicles at or soon after birth are the most common clinical presentation of neonatal HSV infection [Table 7]. In disseminated disease, vesicles may not develop during entire course of the disease in over 20% of cases. Fever and lethargy are common in disseminated and CNS disease. CNS involvement in the form of encephalitis, which presents as seizures, is also seen in 60-75% of neonates with disseminated disease. The diagnosis is established by polymerase chain reaction (PCR) which has a sensitivity and specificity ranging from 75 to 100% and 71 to 100% respectively. [29],[30],[31] The detection of HSV DNA in CSF at the end of treatment is associated with poor outcomes. The acyclovir therapy should be continued in such patients till the CSF PCR becomes negative. The incidence of mortality associated with various types of neonatal herpes has declined significantly from pre-acyclovir era to the present era. [32],[33] The high dose and longer duration of acyclovir therapy has shown better results in terms of incidence of neurologic sequele, mortality, morbidity and relapse of the disease especially when HSV-2 is the causative agent. [34] Mortality has declined from 85 to 29% in disseminated disease (DIC, severe hepatitis, pneumonia) and from 50 to 4% in CNS disease (acute neurologic and autonomic dysfunction). [26]

Candidiasis in newborns occurs in two forms, congenital cutaneous candidiasis (CCC) and neonatal candidiasis. The former is acquired in utero and the latter during the passage through infected birth canal. The classical clinical presentation of CCC is a generalized erythematous macules, papules and/ or pustules measuring 2-4 mm on an erythematous base distributed predominantly over back, extensor extremities and skin folds, and almost always involving the palms and soles. The diaper area is usually spared and the oral mucosa is rarely involved. Over a span of few days the initial lesions evolve into pustules, vesicles and sometimes, bullae. The infection of nails can also occur occasionally in the form of onychia or paronychia. The lesions generally resolve with desquamation within 1-2 weeks. [35],[36] Burn like dermatitis can occur in term infants which precedes systemic involvement. [37] The clinical presentation differs in premature infants weighing <1000g [Table 7]. Neonatal candidiasis on the other hand manifests after 7 days of life and is localized to oral cavity and diaper. However, in extremely low birth weight infants, the neonatal candidiasis may present as invasive fungal dermatitis. [38] In full-term infants, CCC follows a benign and self- limited course. CCC and neonatal candidiasis can progress to systemic candidiasis in neonates with certain risk factors [Table 7]. [36] Cultures of blood, urine and cerebrospinal fluid (CSF) should be done whenever systemic infection is suspected, and in all premature infants. Respiratory distress in immediate neonatal period should arouse the suspicion of systemic involvement. Systemic involvement and mortality in neonates with CCC, weighing < 1000g, occur in 67% and 40% of cases respectively when compared to those weighing > 1000g (10% and 8% respectively). [39] Antifungal therapy for CCC in a term infant has not shown any benefit. However, some authors recommend topical or oral therapy to decrease the number of viable organisms on the skin. [40] Respiratory distress, leukocytosis with immature forms, persistent hyperglycemia and glycosuria, positive cultures from blood, urine or CSF, burn like dermatitis, and extensive instrumentation and invasive procedures are the indications for systemic therapy in CCC. [36] Intravenous amphotericin B is the first line of drug [Table 7]. Fluconazole 6 mg/kg/day intravenously can also be used if the neonate develops intolerance to amphotericin B. [41] Newer broad spectrum systemic antifungals like voriconazole (4 mg/kg/day), [42] capsofungin (25 mg/m 2 /day, 1 h infusion) [43] and micafungin (2 mg/kg/day) [44] have been used in combination with or following initial amphotericin B therapy in critically ill neonates with systemic candidiasis.

C. Epidermolysis bullosa

Epidermolysis bullosa (EB) is a group of inheritable mechanobullous disorders with a tendency to develop vesicles and bullae at the site of trivial trauma. Depending upon the level of defect and bullae in the basement membrane zone, EB is divided into three types: EB simplex (EBS), junctional EB (JEB) and dystrophic EB (DEB). Among several subtypes of EB, severe form of EBS-Dowling- Meara (EBS-DM), Herlitz-type JEB (JEB-H) and recessive DEB (RDEB) can be lethal in neonatal period. [45]

Clinical features: In severe cases of EBS-DM, extensive blisters may appear spontaneously particularly in hot environment. Bullae appear more hemorrhagic than in other types of EBS. Hands and feet are the predilected sites. Laryngeal involvement can also occur resulting in a weak cry. These neonates are more susceptible to recurrent infections and septicemia caused by S. aureus and P. aeruginosa. [46] Death in neonatal period is not infrequent. JEB-H is characterized by generalized cutaneous and mucosal erosions. Blisters and erosions are large and extensive seen at or soon after birth. Severe involvement of back and buttocks is common. Involvement of respiratory epithelium may result in stridor which can be fatal. In RDEB, blisters begin at birth and can be extensive. Extracutaneous involvement including gastrointestinal tract, genitourinary tract and ocular mucosa is common. Variable degree of nail changes is common in both JEB-H and RDEB. In neonatal period, sepsis is the worrisome problem and can lead to death in these severe forms of EB. [45]

Diagnosis: Transmission electron microscopy is the gold standard for the diagnosis of EB. But it is time consuming and labor- intensive. Immunofluorescence study is the preferred method of rapid diagnosis of EB. Skin biopsy helps in differentiating other vesiculobullous disorders. [45]

Treatment: There is no specific therapy for EB. The neonate should be treated in neonatal intensive care unit specialized in EB. Radiant warmer and incubator should be avoided unless the newborn is of low birth weight. The main goals of care are minimizing new blister formation, maintenance of cooler environment temperature, promotion of wound healing, prevention of sepsis and adequate nutritional supplementation. In addition, correction of fluid and electrolyte imbalance, treatment of sepsis and administration of sufficient calories to meet added metabolic demands is very essential in severe cases. [45]

D. Neonatal biotin deficiency

Holocarboxylase synthetase (HCS) deficiency causes neonatal biotin deficiency which usually manifests during first 6 weeks of life. Biotinidase deficiency causes infantile biotin deficiency after first 3 months of life. Biotin is required for the function of four carboxylase enzymes involved in fatty acid synthesis, gluconeogenesis and amino acid catabolism. These enzymes become active when biotin is linked to inactive apocarboxylase by the enzyme holocarboxylase synthetase. [47]

Clinical features: HCS deficiency causes severe bilaterally symmetrical well demarcated periorificial and intertriginous dermatitis and universal alopecia. [48] The neonate usually presents with severe metabolic acidosis and organic aciduria. Seizures, lethargy, projectile vomiting, abnormal muscle tone, athetosis, progressive loss of consciousness and coma are the other manifestations. HCS deficiency in a newborn presenting as collodion membrane with severe metabolic acidosis has been described. The presence of severe metabolic acidosis in a neonate with collodion membrane or ichthyosis may be considered as an indication for evaluation of HCS deficiency. [47] Neonatal biotin deficiency is fatal if not treated or diagnosed early. [47],[48]

Diagnosis: The diagnosis is established by estimation of urinary organic acid excretion. 3-hydroxyisovaleric acid is the major metabolite excreted in biotin deficiency. Low carboxylase activities can be confirmed by enzyme assays. Poor incorporation of biotin into the carboxylases, and low transfer of biotin by the holocarboxylase synthetase enzyme are demonstrated by fibroblast analysis. [49]

Treatment: The dosage of biotin is usually high 20- 40 mg/day and sometimes 100 mg/day may be required. The signs and symptoms resolve completely following biotin therapy. Treatment with biotin gradually improves the biochemical abnormalities in blood and in cerebrospinal fluid (CSF), corrects the carboxylase enzyme activities, and provides clinical stability and a normal neurodevelopmental outcome. The biotin supplementation is required for life long. [48],[49]

E. Kasabach-Merritt phenomenon

Kasabach-Merritt phenomenon (KMP) is a clinical syndrome of thrombocytopenic coagulopathy in association with vascular tumor. It is usually seen in infants lesser than 3 months of age. It is caused by sequestration of platelets, accumulation of activated coagulation factors and local fibrinolysis in a vascular tumor. The common underlying vascular tumors are tufted angioma and Kaposi's hemangioendothelioma. [50] The latter is almost always associated with KMP. [51]

Clinical features: The onset of Kasabach-Merritt phenomenon is heralded by a sudden and rapid increase in the volume of the tumor, a change to a deep violet color and by the appearance of ecchymosis. These most commonly occur on the trunk, neck and proximal parts of the limbs. The rapidly enlarging tumor may compress the vital structures and the thrombocytopenia may cause acute hemorrhage in various internal organs (DIC). [52] In an infant, any rapidly growing vascular tumor with or without ecchymosis should be evaluated for both cutaneous and visceral KMP. The disease causes mortality in 20-30% of patients. [53]

Diagnosis: Laboratory evidence of consumptive coagulopathy (prolonged prothrombin and activated partial thromboplastin time, reduced fibrinogen, and elevated D-dimer levels) and thrombocytopenia along with clinical course of the tumor confirm the diagnosis of KMP. Destructive vascular lesions on MRI aid in the diagnosis of visceral KMP. [51]

Treatment: A combination therapy is necessary as no single treatment modality is universally effective. Early initiation of oral corticosteroid therapy with prednisolone at 2-5 mg/kg/day is effective in increasing the platelet count and decreasing the size of the tumor. Prednisolone is ineffective if the coagulopathy is very severe. Vincristine in the dose of 1-1.5 mg/m 2 /week as slow intravenous infusion for 7 weeks is also effective and can be used as first line of treatment. [54] Surgical excision with prior platelet transfusion is recommended for well circumscribed, small and superficial tumor. Embolization is an extremely valuable treatment which results in a rapid and permanent reversal of coagulopathy. Platelet transfusion is indicated prior to surgical procedures including embolization to achieve hemostasis. Otherwise, it is indicated only when there is severe bleeding. Supportive therapy with fresh frozen plasma and cryoprecipitate may be useful. [51]

  2. Dermatoses Associated with Medical or Surgical Emergencies Top

A. Purpura fulminans

Purpura fulminans (PF) is an acute syndrome characterized by rapidly progressive skin necrosis and disseminated intravascular coagulation (DIC). [55]

Hereditary (congenital) protein C deficiency manifesting at birth is caused by homozygous or compound heterozygous mutations in PROC gene resulting in absolute deficiency of protein C. The condition is inherited as autosomal recessive disorder. [56]

Acute infectious PF in neonates is commonly caused by group B streptococcal septicemia. Gram negative septicemia due to  Escherichia More Details coli and Enterobacter, and staphylococcal septicemia may also cause PF in neonates. [57]

Clinical features: PF due to homozygous Protein C deficiency manifests from 2 h to 2 weeks after birth. The life threatening thrombotic event involves skin, central nervous system, eyes and kidney. [58] The clinical manifestation is characterized by sudden onset of widespread purpura commonly involving extremities, though any parts of the body may be affected. Soon the lesions enlarge and vesiculate forming hemorrhagic bullae. Subsequently the skin undergoes necrosis resulting in black eschar formation. The margins of the lesions are well demarcated, erythematous and indurated. The cutaneous manifestations culminate in DIC with associated internal bleeding. [59] In acute infectious PF, the characteristic lesions occur in a neonate with associated signs of septicemia. [60]

The estimation of Protein C activity is a reliable test to diagnose hereditary Protein C deficiency. In homozygous form, the Protein C activity is markedly decreased to <0.02 IU/ml (Lower normal limit, 0.67-0.72 IU/ml). The levels above 0.03-0.05 IU/ml are sufficient to ameliorate the symptoms of PF. [61] Increased D-dimer levels, low fibrinogen, increased fibrinogen degradation products (FDP), low platelet count, and prothrombin fragment 1.2 indicate DIC. These parameters along with clinical response are useful in monitoring and optimizing Protein C therapy. [62] Relevant investigations as indicated by clinical features should be done to know the involvement of central nervous system, kidney and eyes. In acute infectious PF, blood culture should be done to identify the causative organism for septicemia.

Treatment: Irrespective of underlying cause, the neonatal PF must be diagnosed and treated rapidly and aggressively [Table 8]. [61] Acute infectious PF can be managed with immediate heparinization, and infusion of FFP (15 ml/kg every 12 h) along with the resuscitation measures for septic shock. [57] Prostacycline, a thromboxane A 2 antagonist, in the initial dose of 5 ng/kg/min, then increased and maintained at 15 ng/kg/min for 48 h has been used successfully in the treatment of acute infectious PF. It has beneficial effects on pulmonary hypertension and thromboxane-induced platelet aggregations which occur in septicemia. [63] The mortality is almost 100% in untreated hereditary neonatal PF, [61] whereas acute infectious PF is associated with 50% mortality. [60]

B. Kawasaki disease

Kawasaki disease is a systemic vasculitis predominantly affecting younger children less than 4 years of age with peak age of onset of 6 to 11 months. [64] The disease is rare in infants below 3 months constituting only 1.7% of total cases. [65] However, there are few reports of neonatal KD. The youngest ever patient is a 2-week-old infant who presented with classical KD. [66] A recent survey suggests that the incidence of KD is rising in India. [67]

Clinical features: Neonatal KD is characterized by atypical presentations and a rapid and severe coronary artery involvement. The atypical presentations include low incidence of conjunctivitis, skin rash and extremity changes, and low C-reactive protein. [68] Lack of awareness of neonatal occurrence of KD is responsible for delay in diagnosis. Classical presentation of KD such as high-grade fever not relieved by antipyretics, generalized erythematous maculopapular rash, bilaterally symmetrical non-pitting edema of hands and feet, fissuring of lips, reddish discoloration of tongue and non-purulent bilateral bulbar conjunctivitis has been reported. [64] Mortality due to KD occurs between 2 and 12 weeks after the onset of illness, and is usually secondary to coronary aneurysms and their complications. Improvement in the early diagnosis and institution of appropriate therapy in the acute phase resulted in decline in mortality from 1-2% (pre IVIg era) to 0.08% (IVIg era). [67] Similarly the coronary artery disease declined from 20-25% to 3-5%. [69]

Diagnosis: Clinical diagnosis of KD in a neonate requires a high index of suspicion. The diagnosis is confirmed by echocardiography. Aneurysmal dilatation of coronary arteries and dysfunction of valves are the common findings on echocardiography. A repeat echocardiography is obtained at 2-3 weeks and again at 6-8 weeks following the onset of illness. Acute phase reactants like C- reactive protein should also be monitored to assess the acute inflammatory phase. [67]

Treatment: The mainstay of treatment is intravenous immunoglobulin (IVIg) along with high dose aspirin. The maximum benefit of IVIg in preventing coronary artery dilatation is seen when it is administrated within first 10 days of illness. The usual dosage schedule is IVIg 2g/kg as single dose and aspirin 30-50 mg/kg/day in three divided doses until the fever subsides (around 14 th day), then 10-30 mg/kg/day till complete disappearance of acute inflammation (usually 6-8 weeks). [67] Not all patients respond to single dose of IVIg. Such resistant patients require second dose of IVIg (2g/kg). [69] Persistence of fever, persistently elevated acute phase reactants (systemic inflammation) and new onset dilatation of coronary arteries are indicators of second dose of IVIg. [68] Newer drugs like infliximab (5 mg/kg over 2 h) have been investigated for safety and tolerability in pediatric patients (youngest, 2 months; oldest 5 years) with KD. Infliximab was found to be safe but the efficacy still needs to be addressed. [69]

C. Sclerema neonatorum

Sclerema neonatorum is regarded as end stage of severe systemic disease. Sclerema is an uncommon, life-threatening condition, usually of newborns, with a case-fatality rate ranging from 50 to 100%. Hypothermia, severe malnutrition, septic shock, serum ammonia and C- reactive protein levels are considered as predictors of mortality. [70]

Clinical features: The disease manifests during first 1-2 weeks of life in severely debilitated term and preterm infants. It is characterized by sudden onset of diffuse hardening of skin initially involving the lower legs and later spreading to thighs, buttocks, trunk, and cheeks. The palms, soles and genitalia are usually spared. The skin is cold, smooth, hard and bound down. [71] Neonates with diarrhoea and sepsis presenting with hypothermia, lower serum protein and prealbumin are prone to develop sclerema. [72]

Diagnosis: The diagnosis is mainly based on characteristic clinical features. Histology of the skin biopsy shows thickening of the trabeculae supporting the subcutaneous adipose tissue and a sparse inflammatory infiltrate of lymphocytes, histiocytes and multinucleate giant cells. The laboratory abnormality may include electrolyte disturbances, hypoglycemia and azotemia. [71]

Treatment: Supportive therapy such as maintenance of body temperature, correction of fluid and electrolyte disturbances, and nutritional supplementation may sometimes reduce the inevitable mortality. Systemic corticosteroids, exchange transfusion and antibiotics have improved the survival rate in infants with sepsis. [71]

  Conclusion Top

With the availability of effective drugs and monitoring facilities, and awareness of need for immediate care, there has been a significant decline in the fatality rate associated with neonatal dermatological emergencies. Knowledge of clinical presentations, rapid diagnostic methods, emergency care and monitoring the progress of the disease help in comprehensive multidisciplinary care of neonates with these disorders.

  References Top

1.Inamadar AC, Palit A. Acute skin failure: Concept, causes, consequences and care. Indian J Dermatol Venereol Leprol 2005;71:379-85.  Back to cited text no. 1  [PUBMED]  Medknow Journal  
2.Sarkar R, Basu S, Patwari AK, Sharma RC, Dutta AK, Sardana K. An appraisal of pediatric dermatological emergencies. Indian Pediatr 2000;37:425-9.  Back to cited text no. 2      
3.Sarkar R. Neonatal and Infantile erythroderma: 'The red baby'. Indian J Dermatol 2006;51:178-81.  Back to cited text no. 3    Medknow Journal  
4.Pruzkowski A, Bodemer C, Fraitag S, Teillac-Hamel D, Amoric JC, Prost YD. Neonatal and Infantile erythroderma. A retrospective study of 51 patients. Arch Dermatol 2000;136:875-80.  Back to cited text no. 4      
5.Sarkar R, Sharma RC, Koranne RV, Sardana K. Erythroderma in children: A clinico-etiological study. J Dermatol 1999;26:507-11.  Back to cited text no. 5      
6.Hoeger PH, Harper JI. Neonatal erythroderma: Differential diagnosis and management of the 'red baby'. Arch Dis Child 1998;79:186-91.  Back to cited text no. 6      
7.Glover MT, Atherton DJ, Levinsky RJ. Syndrome of erythroderma failure to thrive and diarrhoea in infancy: A manifestation of immunodeficiency. Pediatrics 1988;81:66-72.   Back to cited text no. 7      
8.Chawla D, Agarwal R, Deorari AK, Paul VK. Fluid and Electrolyte management in term and preterm neonates. Indian J Pediatr 2008;75:255-9.  Back to cited text no. 8      
9.Modi N. Management of fluid balance in the very immature neonate. Arch Dis Chil Fetal Neonatal Ed 2004;89:F108-11.  Back to cited text no. 9      
10.Shwayder T, Akland T. Neonatal skin barrier: Structure, function, and disorders. Dermatol Ther 2005;18:87-103.  Back to cited text no. 10      
11.Buyse L, Graves C, Marks R, Wijeyesekera K, Alfaham M, Finlay AY. Collodion baby dehydration: the danger of high tranepidermal water loss. Br J Dermatol 1993;129:86-8.  Back to cited text no. 11      
12.Mosowtz DG, Fowler AJ, Heyman MB, Cohen SP, Crumrine D, Elias PM. Pathophysiologic basis for growth failure in children with ichthyosis: an evaluation of cutaneous ultrastructure, epidermal permeability barrier function, and energy expenditure. J Pediatr 2004;145:82-92.  Back to cited text no. 12      
13.Elias PM, Williams LM, Wolleran WM, Jiang YJ, Schumth M. Pathogenesis of permeability barrier abnormalities in ichthyosis: Inherited disorders of lipid metabolism. J Lipid Res 2008;49:694-714.  Back to cited text no. 13      
14.Iyer PU. Nutritional support in the critically ill child. In: Udani S, Ugra D, Chugh K, Khilnani P, editors. IAP specialty series on Pediatric intensive care. New Delhi: JayPee Brothers Medical Publishers (P) Ltd; 2008. p. 408-15.  Back to cited text no. 14      
15.Williams ML, Bruckner AL, Nopper AJ. Generalized disorders of cornification (the ichthyoses). In: Harper J, Oranje A, Prose N, editors. Textbook of Pediatric Dermatology. 2nd ed. Oxford: Blackwell Publishing; 2006. p. 1304-58.  Back to cited text no. 15      
16.Ladhani S, Joannou CL, Lochrie DP, Evans RW, Poston SM. Clinical, microbial, and biochemical aspects of exfoliative toxins causing Staphylococcal scalded skin syndrome. Clin Microbiol Rev 1999;12:224-42.  Back to cited text no. 16      
17.Makhoul IR, Kassis I, Hashman N, Sujov P. Staphylococcal scalded skin syndrome in very low birth weight premature infant. Pediatrics 2001;108:E16.  Back to cited text no. 17      
18.Ladhani S, Garbash M. Staphylococcal skin infections in children. Rational drug therapy recommended. Pediatr Drug 2006;7:77-102.  Back to cited text no. 18      
19.Hsieh WH, Yang PH, Chao HC, Lai JY. Neonatal necrotizing fascitis: A report of three cases and review of literature. Pediatrics 1999;103:e53.  Back to cited text no. 19      
20.Green RJ, Dafoe DC, Raffin TA. Necrotizing fascitis. Chest 1996;110:219-29.  Back to cited text no. 20      
21.Moss RL, Musemeche CA, Kosloske AM. Necrotizing fascitis in children: prompt recognition and aggressive therapy improve survival. J Pediatr Surg 1996;31:1142-6.  Back to cited text no. 21      
22.McHenry CR, Piotrowski JJ, Petrinic D, Malangoni MA. Determinants of mortality for necrotizing soft-tissue infections. Ann Surg 1995;221:558-65.  Back to cited text no. 22      
23.Sauerbrei A, Wutzler P. Neonatal varicella. J Perinatol 2001;21:545-9.  Back to cited text no. 23      
24.Sterner G, Forsgren M, Enocksson E, Grandien M, Granstro'm G. Varicella -zoster infections in late pregnancy. Scand J Infect Dis 1990;71:30-5.   Back to cited text no. 24      
25.Prober CG, Gershon AA, Grose C, McCracken GH, Nelson JD. Consensus: varicella - zoster infections in pregnancy and the neonatal period. Pediatr Infect Dis J 1990;9:865-9.  Back to cited text no. 25      
26.Kimberlin DW. Neonatal herpes simplex infection. Clin Microbiol Rev 2004;17:1-13.   Back to cited text no. 26      
27.Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003;289:203-9.  Back to cited text no. 27      
28.Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Frenkel LM, Gruber WC, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 2001;108:223-9.   Back to cited text no. 28      
29.Kimberlin DW, Lakeman FD, Arvin AM, Prober CG, Corey L, Powell DA, et al. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. J Infect Dis 1996;174:1162-7.  Back to cited text no. 29      
30.Kimura H, Futamura M, Kito H, Ando T, Goto M, Kuzushima K, et al. Detection of viral DNA in neonatal herpes simplex virus infections: frequent and prolonged presence in serum and cerebrospinal fluid. J Infect Dis 1991;164:289-93.  Back to cited text no. 30      
31.Troendle-Atkins J, Demmler GJ, Buffone GJ. Rapid diagnosis of herpes simplex virus encephalitis by using the polymerase chain reaction. J Pediatr 1993;123:376-80.   Back to cited text no. 31      
32.Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Corey L, Gruber WC, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 2001;108:230-8.   Back to cited text no. 32      
33.Kimberlin DW. Advances in the treatment of neonatal herpes simplex infections. Rev Med Virol 2001;11:157-63.   Back to cited text no. 33      
34.Kimura H, Futamura M, Ito Y, Ando Y, Hara S, Sobajima H, et al. Relapse of neonatal herpes simplex virus infection. Arch Dis Child Fetal Neonatal Ed 2003;88:F483-6.  Back to cited text no. 34      
35.Chapman RL. Candida infections in neonate. Curr Opin Pediatr 2003;15:91-102.  Back to cited text no. 35      
36.Darmstadt GL, Dinulos JG, Miller Z. Congenital cutaneous candidiasis: Clinical presentation, pathogenesis, and management guidelines. Pediatrics 2000;105:438-44.  Back to cited text no. 36      
37.Pradeepkumar VK, Rajaurai VS, Tan KW. Congential candidiasis: Varied presentations. J Perinatol 1998;18:311-6.  Back to cited text no. 37      
38.Rowen JL, Atkins JT, Levy ML, Baer SC, Baker CJ. Invasive fungal dermatitis in the ≤1000-gram neonate. Pediatrics 1995;95:682-7.  Back to cited text no. 38      
39.Baley JE, Silverman RA. Systemic candidiasis: Cutaneous manifestations in low birth weight infants. Pediatrics 1998;2:211-5.   Back to cited text no. 39      
40.Johnson DE, Thompson TR, Ferrieri P. Congenital candidiasis. Am J Dis Child 1981;135:273-5.  Back to cited text no. 40      
41.Leibovitz E. Neonatal candidosis: Clinical picture, management controversies and consensus, and new therapeutic options. J Antimicrobiol Chemo 2002;49:69-73.  Back to cited text no. 41      
42.Kohli V, Taneja V, Sachdev P, Joshi R. Voriconazole in Newborns. Indian Pediatr 2008;45:236-8.  Back to cited text no. 42      
43.Sαez-Llorens X, Macias M, Maiya P, Pineros J, Jafri HS, Chatterjee A, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009;53:869-75.  Back to cited text no. 43      
44.Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: Substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008;27:820-6.  Back to cited text no. 44      
45.Bruckner AL. Epidermolysis bullosa. In: Eichenfield LF, Frieden IJ, Esterly NB, editors. Neonatal Dermatology. 2nd ed. Philadelphia: Saunders; 2008. p. 159-72.  Back to cited text no. 45      
46.Titeux M, Mazereeuw- Hautier J, Hadj-Rabia S, Prost C, Tonasso L, et al. Three severe cases of EBS Dowling- Meara caused by missense and frameshift mutations in the keratin 14 gene. J Invest Dermatol 2006;126:773-6.   Back to cited text no. 46      
47.Arbuckle HA, Morelli J. Holocarboxylase synthetase deficiency presenting as ichthyosis. Pediatr Dermatol 2006;23:142-4.  Back to cited text no. 47      
48.Seymons K, De Moor A, De Raeve H, Lambert J. Dermatologic signs of biotin deficiency leading to diagnosis of multiple carboxylase deficiency. Pediatr Dermatol 2004;21:231-35.  Back to cited text no. 48      
49.Van Hove JL, Josefsberg S, Freehauf C, Thomas JA, Thuy le P, Barshop BA, et al. Management of a patient with holocarboxylase synthetase deficiency. Mol Genet Metab 2008;95:201-5.  Back to cited text no. 49      
50.Rodriguez V, Lee A, Witman PM, Anderson PA. Kasabach-Merritt phenomenon: Case series and retrospective review of the mayo clinic experience. J Pediatr Hematol Oncol 2009;31:522-6.  Back to cited text no. 50      
51.Fernαndez Y, Bernabeu-Wittel M, Garcνa-Morillo JS. Kaposiform hemangio-endothelioma. Eur J Intern Med 2009;20:206-13.  Back to cited text no. 51      
52.Sarkar M, Mulliken JB, Kozakewich HP, Robertson RL, Burrows PE. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Recostr Surg 1997;100:1377-86.  Back to cited text no. 52      
53.Maguiness S, Guenther L. Kasabach-Merritt syndrome. J Cut Med Surg 2002;6:335-9.  Back to cited text no. 53      
54.Haisley-Royster C, Enjolras O, Frieden IJ, Garzon M, Lee M, Oranje A, et al. Kasabach-merritt phenomenon: A retrospective study of treatment with vincristine. J Pediatr Hematol Oncol 2002;24:459-62.  Back to cited text no. 54      
55.Edlich RF, Cross CL, Dahlstrom JJ, Long WB 3rd. Modern concepts of the diagnosis and treatment of purpura fulminans. J Environ Pathol Toxicol Oncol 2008;27:191-6.  Back to cited text no. 55      
56.Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost 1990;60:299-309.  Back to cited text no. 56      
57.Hon KL, So KW, Wong W, Cheung KL. Spot diagnosis: An ominous rash in a newborn. Ital J Pediatr 2009;35:10-2.  Back to cited text no. 57      
58.Churchill AJ, Callagher MJ, Bradbury JA. Clinical manifestations of protein C deficiency: a spectrum within one family. Br J Ophthalmol 2001;85:241-2.  Back to cited text no. 58      
59.Sen K, Roy A. Management of neonatal purpura fulminans with severe Protein C deficiency. Indian Pediatr 2006;43:542-5.  Back to cited text no. 59      
60.Lokeshwar MR, Singhal T, Udani SV, Kapadia SN. Treatment of acute infectious purpura fulminans with activated Protein C. Indian Pediatr 2006;43:535-8.  Back to cited text no. 60      
61.Knoebl PN. Severe congenital protein C deficiency: The use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications. Biologics 2008;2:285-96.  Back to cited text no. 61      
62.Mόller FM, Ehrenthal W, Hafner G, Schranz D. Purpura fulminans in severe congenital protein C deficiency: Monitoring of treatment with protein C concentrate. Eur J Pediatr 1996;155:20-5.  Back to cited text no. 62      
63.Winrow AP. Successful treatment of neonatal purpura fulminans with epoprostenol. J R Soc Med 1992;85:45.  Back to cited text no. 63      
64.Thapa R, Pramanik S, Dhar S, Kundu R. Neonatal Kawasaki disease with multiple coronary aneurysms and thrombocytopenia. Pediatr Dermatol 2007;24:662-4.  Back to cited text no. 64      
65.Tsuchida S, Yamanaka T, Tsuchida R, Nakamura Y, Yashiro M, Yanagawa H. Epidemiology of infant Kawasaki disease with a report on the youngest neonatal case reported in Japan. Acta Pediatr 1996;85:995-7.  Back to cited text no. 65      
66.Stanley TV, Grimwood K. Classical Kawasaki disease in a neonate. Arch Dis Child Fetal Neonatal Ed 2002;86:35-6.  Back to cited text no. 66      
67.Singh S, Kawasaki T. Kawasaki disease-An Indian perspective. Indian Pediatr 2009;46:563-71.  Back to cited text no. 67      
68.Bhatt M, Anil SR, Shivakumar, Kumar K. Neonatal Kawasaki disease. Indian J Pediatr 2004;71:353-4.  Back to cited text no. 68      
69.Burns JC. Kawasaki disease update. Indian J Pediatr 2009;76:71-5.  Back to cited text no. 69      
70.Chisti MJ, Saha S, Roy CN, Ahmed T, Faruque AS, Salam MA, Islam S. Predictors of mortality in infants with sclerema presenting to the centre for diarrhoeal disease, Dhaka. Ann Trop Pediatr 2009;29:45-50.  Back to cited text no. 70      
71.Zeb A, Darmstadt GL. Sclerema neonatorum: a review of nomenclature, clinical presentation, histological features, differential diagnoses and management. J Perinatol 2008;28:453-60.  Back to cited text no. 71      
72.Chisti MJ, Ahmed T, Faruque AS, Saha S, Salam MA, Islam S. Factors associated with sclerema in infants with diarrhoeal disease: A matched case-control study. Acta Pediatr 2009;98:873-8.  Back to cited text no. 72      


  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7], [Table 8]

This article has been cited by
1 Transepidermal Water Loss in Neonates: Baseline Values Using a Closed-Chamber System
Teena R. Mathanda,Ramesh M. Bhat,Pavan Hegde,Shivaraja Anand
Pediatric Dermatology. 2016; 33(1): 33
[Pubmed] | [DOI]
2 Ichthyosis in the Neonatal Setting
Johanna M. Ivich
Advances in Neonatal Care. 2015; 15(4): 253
[Pubmed] | [DOI]


Print this article  Email this article
Previous article Next article


Online since 15th March '04
Published by Wolters Kluwer - Medknow